Big billing for Amgen's tarlatamab in SCLC

13 November 2023

Tarlatamab demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial in lung cancer.

According to GlobalData, US biotech major Amgen’s (Nasdaq: AMGN) bispecific T-cell engager (BiTE) may become a promising lifeline for small cell lung cancer (SCLC) patients - who comprise 15% of 15% of lung tumor patients - and is forecast to achieve peak sales of $788 million by 2029.

Verona Morina, oncology and hematology analyst at the data and analytics provider, said: “The most recent results displayed by tarlatamab may reignite interest in the delta-like ligand 3 (DLL3) antigen present on tumor cells, a target that suffered a setback when AbbVie (NYSE: ABBV) terminated Rova-T, an anti-DLL3 antibody-drug conjugate in 2019, due to its Phase III failure in the treatment of SCLC.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK